Finance

Beta
Lists
Q4 2026 earnings • released • EPS miss -5.56%
See results
REPL:NASDAQ
Replimune Group Inc
$11.15
+0.72%
(+0.080) 1D
Jul 1, 1:49:04 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for REPL...
Open
$11.10
High
$11.70
Low
$11.05
Mkt. cap
935.99M
Avg. vol.
5.77M
Volume
1.40M
52-wk high
$13.24
52-wk low
$1.50
EPS
-$3.44
Beta
0.91
Shares outstanding
83.94M
No. of employees
465
Open
$11.10
High
$11.70
Low
$11.05
Mkt. cap
935.99M
Avg. vol.
5.77M
Volume
1.40M
52-wk high
$13.24
52-wk low
$1.50
EPS
-$3.44
Beta
0.91
Shares outstanding
83.94M
No. of employees
465
News stories
From sources across the web
About Replimune Group Inc
CEO-
Employees465
Founded2015
HeadquartersWoburn, Massachusetts, United States
SectorBiotechnology
Websitereplimune.com
Analyst ratings
Based on 8 analysts giving stock ratings to REPL in the past 3 months
Hold
Buy
2
Hold
5
Sell
1
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for REPL in the last 3 months.
Highest
Current $11.15
$17.00 (+52.47%)
Average
$9.60 (-13.90%)
Lowest
$2.00 (-82.06%)
Analyst
Recommendation
Action
Price target
Projected
Date
Anupam Rama
J.P. Morgan
Buy
Upgraded
$17.00
+52.5%
06/30/2026
Evan Seigerman
BMO Capital
Buy
Upgraded
$16.00
+43.5%
06/30/2026
Robert Driscoll
Wedbush
Hold
Reiterated
$9.00
-19.3%
06/30/2026
Jonathan Chang
Leerink Partners
Hold
Reiterated
-
-
06/02/2026
Robert Burns
H.C. Wainwright
Sell
Downgraded
-
-
04/13/2026
Roger Song
Jefferies
Hold
Downgraded
$2.00
-82.1%
04/12/2026
Li Watsek
Cantor Fitzgerald
Hold
Downgraded
-
-
04/10/2026
Allison Bratzel
Piper Sandler
Hold
Downgraded
$4.00
-64.1%
04/10/2026
Last report
Jun 29, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
-$0.76 / -$0.72
-5.56%miss
Revenue / Est. (USD)
- / 3.57M
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
53.20M
57.20M
57.28M
52.58M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
25.57M
32.80M
26.64M
18.95M
Operating expense
78.78M
90.00M
83.91M
71.53M
Total operating expenses
78.78M
90.00M
83.91M
71.53M
Operating income
-78.78M
-90.00M
-83.91M
-71.53M
Other non operating income
-
-
-
-
EBT including unusual items
-74.24M
-86.69M
-83.10M
-71.24M
EBT excluding unusual items
-74.24M
-86.69M
-83.10M
-71.24M
Income tax expense
-107.00K
-
-
-311.00K
Effective tax rate
0.14%
-
-
0.44%
Other operating expenses
-
-
-
-
Net income
-74.13M
-86.69M
-83.10M
-70.93M
Net profit margin
-
-
-
-
Earnings per share
-0.82
-0.95
-0.90
-0.77
Interest and investment income
5.88M
4.71M
3.70M
2.85M
Interest expense
-1.98M
-2.00M
-2.01M
-1.98M
Net interest expenses
3.89M
2.72M
1.69M
866.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-75.10M
-89.43M
-83.37M
-69.16M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer